The complexity of the therapeutic approach in systemic lupus erythematosus (SLE) is increased by the large number of patients who do not respond to the first-line therapies and by relapses after initial clinical remission. In these patients, second-line drugs are often prescribed according to individual clinical decisions. The emergence of biological therapies has increased the therapeutic armamentarium available in these complex situations, but their use is limited by the lack of licensing. Available data on the use of rituximab in SLE rely on a large number of case reports and some observational studies. We analyzed current evidence on the therapeutic use of rituximab in adult SLE patients by a systematic review of reports included in the PubMed database between 2002 and 2007. A total of 188 SLE patients treated with rituximab were identified; 171 (91%) patients showed a significant improvement in one or more of the systemic SLE manifestations. There were 103 patients with lupus nephritis, with an overall rate of therapeutic response of renal involvement of 91%. Adverse events were reported in 44 (23%) patients; the most frequent were infections (19%). Although it is not yet possible to make definite recommendations, the global analysis of all cases reported to date support the off-label use of rituximab in severe, refractory SLE cases, whereas its use as a first-line therapy or in patients with a predominantly mild form of the disease is not advised.
1 Furst DE Keystone EC Kirkham B . Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis2008; 67(Suppl. 3): iii2–iii25.
2.
2 Toloza SM Roseman JM Alarcon GS . Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage. Arthritis Rheum2004; 50: 3177–3186.
3.
3 Urowitz MB Gladman DD . How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology (Oxford)2000; 39: 238–244.
4.
4 Font J Cervera R Ramos-Casals M . Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin Arthritis Rheum2004; 33: 217–230.
5.
5 Driver CB Ishimori M Weisman MH . The B cell in systemic lupus erythaematosus: a rational target for more effective therapy. Ann Rheum Dis2008; 67: 1374–1381.
6.
6 Cervera R Khamashta MA Font J . Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore)2003; 82: 299–308.
7.
7 Bertsias G Ioannidis JP Boletis J . EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis2008; 67: 195–205.
8.
8 Looney RJ Anolik J Sanz I . B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells. Lupus2004; 13: 381–390.
9.
9 Chan OT Hannum LG Haberman AM Madaio MP Shlomchik MJ . A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med1999; 189: 1639–1648.
10.
10 Chan OT Madaio MP Shlomchik MJ . B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity. J Immunol1999; 163: 3592–3596.
11.
11 Swaak A van den Brink HG . Case report: common variable immunodeficiency in a patient with systemic lupus erythematosus. Lupus1996; 5: 242–246.
12.
12 Odendahl M Jacobi A Hansen A . Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol2000; 165: 5970–5979.
13.
13 Eisenberg R Albert D . B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol2006; 2: 20–27.
14.
14 Anolik JH Barnard J Cappione A . Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum2004; 50: 3580–3590.
15.
15 Sutter JA Kwan-Morley J Dunham J . A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin Immunol2008; 126: 282–290.
16.
16 Smith MR . Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene2003; 22: 7359–7368.
17.
17 Leandro MJ Edwards JCW Cambridge G Ehrenstein MR . B-cell repopulation occurs mainly from naive B cells in patients with rheumatoid arthritis and systemic lupus erythematosus treated with rituximab. Arthritis Rheum2003; 48(Suppl.): S464 (abstract).
18.
18 Cambridge G Isenberg DA Edwards JC . B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis2008; 67: 1011–1016.
19.
19 Armstrong D Wright S McVeigh C Finch M . Infective endocarditis complicating rituximab (anti-CD20 monoclonal antibody) treatment in an SLE patient with a past history of Libman-Sacks endocarditis: a case for antibiotic prophylaxis? Clin Rheumatol2006; 25: 583–584.
21 Chehab G Sander O Fischer-Betz R Schneider M . Anti-CD20 therapy for inducing and maintaining remission in refractory systemic lupus erythematosus. Z Rheumatol2007; 66: 330–336.
22.
22 Fra GP Avanzi GC Bartoli E . Remission of refractory lupus nephritis with a protocol including rituximab. Lupus2003; 12: 783–787.
23.
23 Gillis JZ Dall'era M Gross A Yazdany J Davis J . Six refractory lupus patients treated with rituximab: a case series. Arthritis Rheum2007; 57: 538–542.
24.
24 Gomard-Mennesson E Ruivard M Koenig M . Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus2006; 15: 223–231.
25.
25 Gottenberg JE Guillevin L Lambotte O . Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis2005; 64: 913–920.
26.
26 Gunnarsson I Sundelin B Jonsdottir T Jacobson SH Henriksson EW van Vollenhoven RF . Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum2007; 56: 1263–1272.
27.
27 Harris HE . Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab. Rheumatology (Oxford)2008; 47: 224–225.
28.
28 Jacobson SH van Vollenhoven R Gunnarsson I . Rituximab-induced long-term remission of membranous lupus nephritis. Nephrol Dial Transplant2006; 21: 1742–1743.
29.
29 Jonsdottir T Gunnarsson I Risselada A Welin Henriksson E Klareskog L van Vollenhoven RF . Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis2008; 67: 330–334.
30.
30 Kotani T Takeuchi T Kawasaki Y . Successful treatment of cold agglutinin disease with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus. Lupus2006; 15: 683–685.
31.
31 Lambotte O Durbach A Kotb R Ferlicot S Delfraissy JF Goujard C . Failure of rituximab to treat a lupus flare-up with nephritis. Clin Nephrol2005; 64: 73–77.
32.
32 Leandro MJ Cambridge G Edwards JC Ehrenstein MR Isenberg DA . B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford)2005; 44: 1542–1545.
33.
33 Lehembre S Macario-Barrel A Musette P Carvalho P Joly P . Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus. Ann Dermatol Venereol2006; 133: 53–55.
34.
34 Looney RJ Anolik JH Campbell D . B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum2004; 50: 2580–2589.
35.
35 Ng KP Cambridge G Leandro MJ Edwards JC Ehrenstein M Isenberg DA . B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis2007; 66: 1259–1262.
36.
36 Perrotta S Locatelli F La Manna A Cennamo L De Stefano P Nobili B . Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol2002; 116: 465–467.
37.
37 Risselada AP Kallenberg CG . Therapy-resistent lupus skin disease successfully treated with rituximab. Rheumatology (Oxford)2006; 45: 915–916.
38.
38 Sabugo F Llanos C Soto L Gutierrez J Cuchacovich M . Rituximab (anti-CD20 monoclonal antibody) for refractory systemic lupus erythematosus: report of one case. Rev Med Chil2005; 133: 681–684.
39.
39 Saigal K Valencia IC Cohen J Kerdel FA . Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab. J Am Acad Dermatol2003; 49: S283–S285.
40.
40 Saito K Nawata M Nakayamada S Tokunaga M Tsukada J Tanaka Y . Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus2003; 12: 798–800.
41.
41 Scheinberg M Hamerschlak N Kutner JM . Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002–2004). Clin Exp Rheumatol2006; 24: 65–69.
42.
42 Sfikakis PP Boletis JN Lionaki S . Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum2005; 52: 501–513.
43.
43 Simon Z Tarr T Ress Z Gergely L Kiss E Illes A . Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma. Rheumatol Int2007; 28: 179–183.
44.
44 Smith KG Jones RB Burns SM Jayne DR . Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum2006; 54: 2970–2982.
45.
45 Tahir H Rohrer J Bhatia A Wegener WA Isenberg DA . Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology (Oxford)2005; 44: 561–562.
46.
46 Tanaka Y Yamamoto K Takeuchi T . A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol2007; 17: 191–197.
47.
47 Tokunaga M Fujii K Saito K . Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford)2005; 44: 176–182.
48.
48 Tokunaga M Saito K Kawabata D . Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis2007; 66: 470–475.
49.
49 Vallerskog T Heimburger M Gunnarsson I . Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther2006; 8: R167.
50.
50 Van den Bergh B Selleslag D Boelaert JR . Management of therapy-resistant systemic lupus erythematosus with rituximab: report of a case and review of the literature. Acta Clin Belg2005; 60: 102–105.
51.
51 van Vollenhoven RF Gunnarsson I Welin-Henriksson E . Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol2004; 33: 423–427.
52.
52 Waite L Morrison E . Severe gastrointestinal involvement in systemic lupus erythematosus treated with rituximab and cyclophosphamide (B-cell depletion therapy). Lupus2007; 16: 841–842.
53.
53 Weide R Heymanns J Pandorf A Koppler H . Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus2003; 12: 779–782.
55 Smolen JS Keystone EC Emery P . Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis2007; 66: 143–150.
56.
56 Silverman GJ . Anti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic. Arthritis Rheum2005; 52: 371–377.
57.
57 Albert D Dunham J Khan S . Variability in the biological response to anti-CD20 B-cell depletion in SLE.Ann Rheum Dis2008; 67: 1724–1731.
58.
58 Calabrese LH Mohillo ES Huang D Ransohoff RM . Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum2007; 56: 2116–2128.
59.
59 Merkel PA Lo GH Holbrook JT . Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener’s Clinical Occurrence of Thrombosis WeCLOT) Study. Ann Intern Med2005; 142: 620–626.
60.
60 Ramos-Casals M Brito-Zerón P Soto MJ Cuadrado MJ Khamashta MA . Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol2008; 22: 847–861.
61.
61 Merrill JT Neuwelt CM Wallace DJ . Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus: results from the randomized, double-blind phse II/III study EXPLORER. Arthritis Rheum2008; 58(Suppl.): L12.
62.
62 Yamamoto M Takahashi H Wakasugi H . Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis. Mod Rheumatol2007; 17: 72–74.
63.
64.
64 Szeto CC Kwan BC Lai FM . Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford)2008; 47: 1678–1681.
65.
65 Tse KC Lam MF Tang SC Tang CS Chan TM . A pilot study on tacrolimus treatment in membranous or quiescent lup us nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus2007; 16: 46–51.
66.
66 Aringer M Steiner G Graninger WB Höfler E Steiner CW Smolen JS . Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum2007; 56: 274–279.
67.
67 Aringer M Graninger WB Steiner G Smolen JS . Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum2004; 50: 3161–3169.
68.
68 van Vollenhoven RF . The Janus of lupus–benefits and risks with B-cell therapy. Lupus2008; 17: 447–449.
